Intravitreally Injected Anti-VEGF Antibody Reduces Brown Fat in Neonatal Mice

Dong Hyun Jo¹,², Sung Wook Park¹,², Chang Sik Cho¹,², Michael B. Powner³, Jin Hyoung Kim¹, Marcus Fruttiger³, Jeong Hun Kim¹,²,⁴*

¹ Fight against Angiogenesis-Related Blindness (FARB) Laboratory, Clinical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea, ² Department of Biomedical Sciences, College of Medicine, Seoul National University, Seoul, Republic of Korea, ³ UCL Institute of Ophthalmology, University College London, London, United Kingdom, ⁴ Department of Ophthalmology, College of Medicine, Seoul National University, Seoul, Republic of Korea

☯ These authors contributed equally to this work.
* steph25@snu.ac.kr

Abstract

Anti-vascular endothelial growth factor (VEGF) agents are the mainstay treatment for various angiogenesis-related retinal diseases. Currently, bevacizumab, a recombinant humanized anti-VEGF antibody, is trailed in retinopathy of prematurity, a vasoproliferative retinal disorder in premature infants. However, the risks of systemic complications after intravitreal injection of anti-VEGF antibody in infants are not well understood. In this study, we show that intravitreally injected anti-VEGF antibody is transported into the systemic circulation into the periphery where it reduces brown fat in neonatal C57BL/6 mice. A considerable amount of anti-VEGF antibody was detected in serum after intravitreal injection. Furthermore, in interscapular brown adipose tissue, we found lipid droplet accumulation, decreased VEGF levels, loss of vascular network, and decreased expression of mitochondria-related genes, Ppargc1a and Ucp1, all of which are characteristics of “whitening” of brown fat. With increasing age and body weight, brown fat restored its morphology and vascularity. Our results show that there is a transient, but significant impact of intravitreally administered anti-VEGF antibody on brown adipose tissue in neonatal mice. We suggest that more attention should be focused on the metabolic and developmental significance of brown adipose tissue in bevacizumab treated retinopathy of prematurity infants.

Introduction

Anti-vascular endothelial growth factor (VEGF) agents are routinely used in various retinal diseases including age-related macular degeneration and diabetic retinopathy [1,2]. Recently, retinopathy of prematurity (ROP) has also been a target of anti-VEGF antibody, bevacizumab (Genentech) [3,4]. The rationale for the use of bevacizumab is the increased level of VEGF in the eyes of patients with ROP, which is secreted in response to hypoxia in non-vascularized retina [5]. In ROP, vasoproliferative changes can lead to vision impairment if they are improperly treated or left untreated.
Although intravitreally injected anti-VEGF therapy is thought to be relatively safe in adults [6], studies on the safety in infants are limited [7]. It is not ideal to use therapeutic agents of which safety has not been guaranteed in premature infants. Unfortunately, indiscriminate use of anti-VEGF agents for ROP can induce vision-threatening complications and lasting ocular structural abnormalities [8,9]. The more important issue is that intravitreally injected anti-VEGF agents can be transported into the blood stream and increase the risk of systemic adverse events [10]. Particularly, neonatal Fc receptors in ocular tissues might affect distribution of intravitreally injected anti-VEGF antibody, which has an Fc domain [11,12].

Anti-VEGF antibody in systemic circulation can affect several organs that require VEGF for normal development in developing premature infants. For instance, brown adipose tissue (BAT) is supported by an extensive vasculature which is dependent on VEGF [13]. In this study, we show that intravitreally injected anti-VEGF antibody transiently reduces brown fat in neonatal mice. Since brown fat plays a crucial role in non-shivering thermogenesis and homeostasis regarding energy metabolism [14,15], even transient impacts on these processes give rise to concern in premature infants.

**Materials and Methods**

**Oxygen-induced retinopathy (OIR)**

C57BL/6 mice were obtained from Central Lab. Animal. OIR was induced in newborn mice as previously described [16,17]. At postnatal day (P)14, we intravitreally injected 1 μL of phosphate-buffered saline (PBS) or anti-mouse VEGF164 antibody (1 μg/eye; cat. no.: AF-493-NA, R&D) into the right eye of mice using NanoFil 10 μL syringe with 35 gauge needle (WPI) after anesthesia using tiletamine plus zolazepam (Zoletil 50, Virbac; 30 mg/Kg) and xylazine (Rompun, Bayer; 10 mg/Kg). At P17, the mice were euthanized by carbon dioxide in deep anesthesia using tiletamine plus zolazepam and xylazine. Then, the enucleated eyes were prepared for immunofluorescent staining of whole mount retinas with Alexa Fluor 594 isolectin GS-IB4 conjugate (5 μg/mL; Invitrogen). The whole mount retinas were viewed with a fluorescence microscope (Eclipse 90i; Nikon). Then, the neovascular tufts were marked and the extent of them were calculated using NIS-Elements AR (v. 3.2; Nikon). The area of neovascular tufts was normalized to the area of whole retina. All animal studies were approved by the Seoul National University Institutional Animal Care and Use Committee and conducted in agreement with the ARVO statement for the use of animals in ophthalmic and vision research.

**Tissue and serum preparation**

After euthanasia by carbon dioxide in deep in deep anesthesia using tiletamine plus zolazepam and xylazine, interscapular BAT was meticulously isolated and divided into 3 pieces for paraffin blocks and preparation of protein and RNA, respectively. Before euthanasia, we collected 150–300 μL fresh blood from mice in deep anesthesia by intracardiac puncture and put it into tubes (cat. no.: 365967; BD). After the incubation of 1 hour at room temperature, the tubes were centrifuged at 7,500 rpm at 4°C for 10 minutes. Serum was transferred to microtubes and stored in a deep freezer for further experiments.

**Enzyme-linked immunosorbent assay (ELISA)**

Protein was isolated from BAT by centrifugation at 12,000 rpm at 4°C for 20 minutes after homogenization in 200 μL RIPA buffer at 4°C. VEGF levels were measured in diluted serum (1:5) and protein soup from BAT with Mouse VEGF ELISA kit (cat. no.: MMV00; R&D). The amount of anti-VEGF antibody in serum was measured using goat IgG ELISA kit (cat. no.:
7520, Alpha Diagnostic). To estimate the level of anti-VEGF antibody using goat IgG ELISA, we utilized PBS as the control. In the other experiments, we tried to maintain consistency by using PBS as the control. All samples were measured twice ($n = 3\sim6$).

**Histologic analysis**

BAT was fixed in 4% paraformaldehyde at 4°C for 18 hours. Hematoxylin and eosin (H&E)-stained slides from paraffin blocks were evaluated to estimate the number of large lipid droplets ($> 50 \mu m^2$) per each field at magnification x400. Quantification was performed with captured images (4 randomly selected ones per mice) using Image J (v. 1.48v; NIH) after 8-bit conversion, establishment of threshold with an IsoData algorithm, and segmentation with a watershed algorithm ($n = 3\sim6$).

**Immunofluorescence staining and immunohistochemistry**

4-μm-thick paraffin sections were incubated at 4°C for 2 hours and processed with sequential immersion in Xylene Substitute (Thermo) and graded ethyl alcohol solutions. Then, antigen retrieval was performed by immersion of sections in 0.1 M sodium citrate (pH 6.8, Sigma) at 120°C for 10 minutes. After the permeabilization with 0.2% Triton X-100 for 15 minutes, we treated the sections with 1X Universal Blocking Reagent (Biogenex) for 10 minutes to minimize nonspecific binding. For immunofluorescence staining of vessels in BAT, the sections were incubated with Alexa Fluor 594 isoelectin GS-IB4 conjugate (4 μg/mL) overnight. Quantification was performed with captured images (4 randomly selected ones per mice) using Image J by the measurement of the proportions of isoelectin B4-positive area per image after 8-bit conversion ($n = 3\sim6$). For immunohistochemistry of UCP1 in BAT, the sections were incubated with primary antibody to UCP1 (1:100, cat. no.: ab10983; abcam) overnight and treated with REAL Detection Systems (Dako) and DAB Kit (Life Technologies) as the manufacturer’s instructions.

**Real-time polymerase chain reaction (PCR)**

Total RNA was isolated from BAT using TRI Reagent (Molecular Research Center) according to the manufacturer’s instructions. cDNA was prepared with High Capacity RNA-to-cDNA kit (Life Technologies). Real-time PCR was performed with StepOnePlus Real-Time PCR System (Life Technologies) with TaqMan Fast Advanced Master Mix (Life Technologies) and specific Gene Expression Assays (cat. no.: 4331182; Life Technologies). Product IDs of Gene Expression Assays for genes are as follows: for *Ucp1*, Mm01244861_m1, for *Ppargc1a*, Mm01208835_m1, for *Cox4i1*, Mm01250094_m1, for *Cox4i2*, Mm00446387_m1, for *Gapdh*, Mm99999915_g1, and for *Rn18s*, Mm03928990_g1. All procedures were performed in accordance with the MIQE guidelines.

**Statistics**

Differences between control and treatment groups were assessed by 2-tailed unpaired T-test using Prism 5 (GraphPad). The mean ± SEM was shown in figures.

**Results and Discussion**

**Intravitreally injected anti-VEGF antibody suppresses retinal neovascularization and is detected in serum**

To investigate anti-angiogenic effects of anti-VEGF antibody on retinal neovascularization, we injected anti-mouse VEGF164 antibody (1 μg) into the vitreous cavity of right eyes of OIR
mice at P14 (S1 Fig). OIR is a well-established animal model of retinal neovascularization in ROP [16,17]. Retinas of OIR mice demonstrate characteristics observed in those of infants with ROP: retinal hypoxia and retinal neovascularization from existing retinal vasculature. As expected, intravitreally injected anti-VEGF antibody effectively reduced the formation of neovascular tufts in OIR mice (Fig 1A). We also found reduced levels of VEGF in the retina (Fig 1B), which was likely to be the cause of reduced neovascularization.

Next, we measured serum levels of anti-VEGF antibody and VEGF to identify systemic consequences of intravitreally administered anti-VEGF antibody. We estimated the level of anti-VEGF antibody through the measurement of goat IgG. In this regard, we utilized PBS for the control vehicle throughout the whole study. Furthermore, the treatment of anti-VEGF antibody in this study definitely mimicked the clinical use of anti-VEGF antibody in premature infants. Interestingly, the serum concentration of anti-VEGF antibody was found to be 207.6 ± 15.01 ng/mL at P17, 3 days after intravitreal injection (Fig 1C). Based on estimated total blood volume at this age (~0.5 mL), this suggests that around 10% of the injected dosage was still present in the serum. Despite anti-VEGF antibody in systemic circulation, we did not observe significant reduction in serum VEGF levels (Fig 1D).

In the early era of bevacizumab use for infants with ROP, it was believed that bevacizumab is too large to be transported into the blood stream [3,18]. However, there have been reports on unanticipated effects of bevacizumab on the opposite eye after intravitreal injection, suggesting systemic effects [19]. The more direct evidence came from pharmacokinetic studies in laboratory animals and humans [20–22]. In particular, in infants with ROP, bevacizumab was also detected and increased until 2 weeks after intravitreal injection [23]. A possible mechanism might operate through neonatal Fc receptor, which is expressed in ocular tissues and is thought to play an important role in the transportation of IgG into the systemic circulation [11,12].

As in Fig 1D, we did not observe significant changes in the level of serum VEGF although we detected anti-VEGF antibody in the serum. However, we decided to proceed further experiments based on following reasons: 1) systemic levels of VEGF do not reflect tissue levels [10,24]. 2) No reduction or paradoxical increase in total VEGF with bevacizumab in serum is not an unexpected finding [25,26]. 3) Furthermore, we aimed to investigate systemic effects of intravitreally injected anti-VEGF antibody even at the concentrations of no definite change in serum VEGF levels.

Intravitreally injected anti-VEGF antibody reduces VEGF in BAT and induces “Whitening” of brown fat

Next, we examined VEGF levels in interscapular BAT at P21 and P28, 1 and 2 weeks after intravitreal injection, respectively. It is notable that the size of interscapular BAT were not significantly changed (data not shown). In contrast, at both time points, intravitreally injected anti-VEGF antibody significantly reduces the level of VEGF in BAT (Fig 2A; P-value = 0.0317 and 0.0086, respectively). We speculated that the reduction in the level of VEGF might be due to direct scavenging of VEGF by anti-VEGF antibody. Targeted genetic deletion of VEGF in adipose tissue has been previously shown to induce indicators of BAT “whitening”, such as lipid droplet accumulation and mitochondrial dysfunction [15]. In keeping with this, in our study, H&E staining demonstrated that anti-VEGF antibody dramatically increased the number of large lipid droplets (> 50 μm²) in BAT (Fig 2B and S2A Fig). BAT is metabolically active and displays higher vascular density [14]. Moreover, VEGF-A is a key factor in governing angiogenesis in adipose tissue [27]. We therefore evaluated the effects of anti-VEGF antibody on vascular network in BAT and found a clear reduction in vessel density, as demonstrated by isolectin B4 staining (Fig 2C and S2B Fig).
VEGF-dependent angiogenesis is known to determine the thermogenic response of BAT [28,29]. Furthermore, it is linked to the expression of key genes involved in thermogenesis and mitochondrial biogenesis in BAT such as \textit{Ppargc1a} and \textit{Ucp1} [30]. Particularly, heat production of BAT is dependent on the action of UCP1 which is specifically expressed in mitochondria and uncouples electron transport from ATP production [31]. We found that intravitreally injected anti-VEGF antibody significantly reduced the expression of \textit{Ppargc1a} and \textit{Ucp1} at P21 and P28 in BAT (Fig 2D). Furthermore, other genes related to mitochondrial function, \textit{Cox4i1} and \textit{Cox4i2}, were also reduced (S2C Fig). Reduced UCP1 expression was also confirmed at protein level (S2D Fig). Taken together, intravitreally administered anti-VEGF antibody induced “whitening” of BAT as systemic deletion or suppression of VEGF [13].

Effects of anti-VEGF antibody on BAT are transient

To investigate long-term effects of a single intravitreal injection of anti-VEGF antibody on BAT, we examined the morphology and vascularity of BAT at P42 and P56, 4 and 6 weeks after intravitreal injection, respectively. BAT recovered its normal morphology without the distinct large lipid droplets seen at the earlier time points (Fig 3A and S3A Fig). Furthermore, the BAT vascular network also appeared to be comparable to normal controls treated with PBS (Fig 3B). Also, the expression of mitochondria-related genes in BAT of mice treated with anti-VEGF antibody was also comparable to that of mice treated only with PBS at this time point (S3B Fig). These results are consistent with a previous study which demonstrated that the introduction of transgenic VEGF-A could rescue BAT whitening in mice with targeted deletion of
Vegfa in adipose tissue [15]. Likewise, with decreasing concentrations of serum anti-VEGF antibody (Fig 1C), the effects by neutralization of VEGF in BAT were also diminished.

Despite systemic transportation of intravitreally administered anti-VEGF antibody, bevacizumab is currently in use for the treatment of infants with ROP. There has been so far no definite evidence of serious and life-threatening complications regarding bevacizumab use [7,18]. Similarly, in our study there was no increased mortality in the mouse pups, and we did not observe any permanent changes in body weight between treatment groups during the study period (Fig 3C).

The lack of serious side effects, despite the pronounced effects on BAT, may be due to the transient nature of the changes in BAT. Furthermore, the thermogenic function of BAT is activated under cold exposure or adrenergic stimulus [27,31]. Because our experimental mouse pups (and premature infants) are not normally exposed to excessive cold, it is possible that transient BAT insufficiencies have therefore no further impact. Nevertheless, whitening of BAT might lead to dysfunction in energy and glucose homeostasis [32]. Similarly, VEGF inhibition in BAT of mice resulted in metabolic defects on high-fat diet and decreased insulin sensitivity [15,28]. BAT also modulates other processes of metabolic homeostasis and might have potential involvement
in regulation of immune system, cardiovascular system, skeletal mass, and bone metabolism [31–33]. In this context, it is necessary to investigate further implications of the effects of intravitreally injected anti-VEGF antibody. In particular, attention should be paid to developmental problems of bone and skeletal muscle associated with proper BAT function in premature infants. Although BAT possibly demonstrates species-specific distribution and functions, the dependence of proper BAT function on VEGF and its implications should be taken into account [13,14,33].

In conclusion, we have shown that intravitreally injected anti-VEGF antibody can have a transient, but significant impact on BAT in neonatal mice. Reduced VEGF levels in BAT were accompanied by reduced vascular density, increased lipid droplet accumulation, and decreased expression of genes related with function of BAT. Because VEGF also plays an important role in the maintenance and development of other organ systems, systemic effects of intravitreally administered anti-VEGF antibody should be considered in developing infants. Thus, our results provide a further rationale for concerns about the use of bevacizumab in the treatment of ROP, which can be successfully overcome by conventional treatment, laser photocoagulation.

Supporting Information

S1 Fig. Schematic diagram of animal study with OIR mice. From P7 to P12, neonatal mice were exposed to hyperoxia (75% O₂). At P14, anti-VEGF antibody was injected into the vitreous cavity of right eyes of mice.

(TIF)
S2 Fig. Effects of intravitreally injected anti-VEGF antibody on BAT of neonatal mice. (A) Quantitative analyses of the number of large lipid droplets (> 50 μm²) per field at x400 magnification (n = 3–6). The effects of anti-VEGF antibody were quantitatively analyzed by comparison to the group treated with intravitreal PBS injection as 100%. (B) Extent of vasculature in BAT according to the treatment with anti-VEGF antibody at P21 and P28. Scale bar, 25 μm. (C) Relative expression of Cox4i1 in interscapular BAT at P21 and P28 (n = 3–6). (D) Relative expression of Cox4i2 in interscapular BAT at P21 and P28 (n = 3–6). (E) Representative images of immunohistochemical staining of UCP1 in interscapular BAT at P28. Scale bar, 50 μm. Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. *P < 0.05; **P < 0.01 (two-tailed, unpaired T-test).

(TIF)

S3 Fig. Long-term effects of intravitreally injected anti-VEGF antibody on BAT. (A) Representative images of H&E staining of interscapular BAT after intravitreal injection of PBS or anti-VEGF antibody. Scale bar, 20 μm. (B) Relative expression of Ppargc1a and Ucp1 in interscapular BAT at P42 and P56 (n = 3–6). Data are presented as mean ± SEM in graphs. Anti-VEGF, anti-VEGF antibody. NS, not significant (two-tailed, unpaired T-test).

(TIF)

Author Contributions
Conceived and designed the experiments: DHJ Jeong Hun Kim. Performed the experiments: DHJ SWP CSC. Analyzed the data: DHJ SWP Jin Hyoung Kim. Contributed reagents/materials/analysis tools: MBP MF. Wrote the paper: DHJ MF Jeong Hun Kim.

References
1. Kim LA, D’Amore PA. A brief history of anti-VEGF for the treatment of ocular angiogenesis. Am J Pathol 2012; 181: 376–379. doi:10.1016/j.ajpath.2012.06.006 PMID: 22749677
2. Jo DH, Kim JH, Kim KW, Suh YG, Kim JH. Allosteric regulation of pathologic angiogenesis: potential application for angiogenesis-related blindness. Arch Pharm Res 2014; 37: 285–298. doi: 10.1007/s12272-013-0324-y PMID: 24395531
3. Mintz-Hittner HA, Kennedy KA, Chuang AZ. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 2011; 364: 603–615. doi: 10.1056/NEJMoa1007374 PMID: 21323540
4. Avery RL. Bevacizumab (Avastin) for retinopathy of prematurity: wrong dose, wrong drug, or both? J AAPOS 2012; 16: 2–4. doi: 10.1016/j.jaapos.2011.11.002 PMID: 2237669
5. Hellstrom A, Smith LE, Dammann O. Retinopathy of prematurity. Lancet 2013; 382: 1445–1457. doi: 10.1016/S0140-6736(13)60178-6 PMID: 23782686
6. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364: 1897–1908. doi: 10.1056/NEJMoa1102673 PMID: 21526923
7. Hard AL, Hellstrom A. On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment—a review. Acta Paediatr 2011; 100: 1523–1527. doi: 10.1111/j.1651-2227.2011.02445.x PMID: 21854449
8. Lee BJ, Kim JH, Heo H, Yu YS. Delayed onset atypical vitreoretinal traction band formation after an intraocular injection of bevacizumab in stage 3 retinopathy of prematurity. Eye (Lond) 2012; 26: 903–909.
9. Leopore D, Quim G, Molle F, Baldascino A, Orazi L, Sammartino M, et al. Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings. Ophthalmology 2014; 121: 2212–2219. doi: 10.1016/j.jophtha.2014.05.015 PMID: 25001158
10. Tolentino M. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. Surv Ophthalmol 2011; 56: 95–113. doi: 10.1016/j.survophthal.2010.08.006 PMID: 21335144
11. Powner MB, McKenzie JA, Christianson GJ, Roopenian DC, Fruttiger M. Expression of neonatal Fc receptor in the eye. Invest Ophthalmol Vis Sci 2014; 55: 1607–1615. doi: 10.1167/iovs.13-12574 PMID: 24550358
12. Kim H, Robinson SB, Csaky KG. FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye. Mol Vis 2009; 15: 2803–2812. PMID: 20019892
13. Bagchi M, Kim LA, Boucher J, Walshe TE, Kahn CR, D’Amore PA. Vascular endothelial growth factor is important for brown adipose tissue development and maintenance. FASEB J 2013; 27: 3257–3271. doi: 10.1096/fj.12-221812 PMID: 23682123

14. Cao Y. Angiogenesis modulates adipogenesis and obesity. J Clin Invest 2007; 117: 2362–2368. PMID: 17786229

15. Shimizu I, Aprahamian T, Kikuchi R, Shimizu A, Papanicolaou KN, Maclauchlan S, et al. Vascular rarefaction mediates whitening of brown fat in obesity. J Clin Invest 2014; 124: 2099–2112. doi: 10.1172/JCI71643 PMID: 24713652

16. Smith LE, Wesolowski E, McLellan A, Kostyk SK, D’Amato R, Sullivan R, et al. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci 1994; 35: 101–111. PMID: 7507904

17. Kim JH, Kim JH, Yu YS, Shin JY, Lee HY, Kim KW. Deguelin inhibits retinal neovascularization by down-regulation of HIF-1alpha in oxygen-induced retinopathy. J Cell Mol Med 2008; 12: 2407–2415. doi: 10.1111/j.1582-4934.2008.00243.x PMID: 18208562

18. Mintz-Hittner HA. Avastin as monotherapy for retinopathy of prematurity. J AAPOS 2010; 14: 2–3. doi: 10.1016/j.jaapos.2009.12.002 PMID: 20227612

19. Avery RL, Pearlman J, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006; 113: 1695.e1–15. PMID:7507904

20. Miyake T, Sawada O, Kakinoki M, Sawada T, Kawamura H, Ogasawara K, et al. Pharmacokinetics of bevacizumab and its effect on vascular endothelial growth factor after intravitreal injection of bevacizumab in macaque eyes. Invest Ophthalmol Vis Sci 2010; 51: 1606–1608. doi:10.1167/iovs.09-4140 PMID: 19875666

21. Wu WC, Lai CC, Chen KJ, Chen TL, Wang NK, Hwang YS, et al. Long-term tolerability and serum concentration of bevacizumab (avastin) when injected in newborn rabbit eyes. Invest Ophthalmol Vis Sci 2010; 51: 3701–3708. doi:10.1167/iovs.09-4425 PMID: 20181842

22. Qian J, Lu Q, Tao Y, Jiang YR. Vitreous and plasma concentrations of apelin and vascular endothelial growth factor after intravitreal bevacizumab in eyes with proliferative diabetic retinopathy. Retina 2011; 31: 161–168. doi: 10.1097/IAE.0b013e3181e48ad8 PMID: 20890241

23. Sato T, Wada K, Arahori H, Kuno N, Imoto K, Iwahashi-Shima C, et al. Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am J Ophthalmol 2012; 153: 327–333. doi: 10.1016/j.ajo.2011.07.005 PMID: 21930258

24. van Wijngaarden P, Coster DJ, Williams KA. Inhibitors of ocular neovascularization: promises and potential problems. JAMA 2005; 293: 1509–1513. PMID: 15784876

25. Stefaniini MO, Wu FT, Mac Gabhann F, Popel AS. Increase of plasma VEGF after intravenous administration of bevacizumab is predicted by a pharmacokinetic model. Cancer Res 2010; 70: 9886–9894. doi:10.1158/0008-5472.CAN-10-1419 PMID: 21118974

26. Gordon MS, Margolin K, Talpaz M, Sledge GW Jr., Holmgren E, Benjamin R, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001; 19: 843–850. PMID:11570338

27. Sun K, Kusminski CM, Luby-Phelps K, Spurgin SB, An YA, Wang QA, et al. Brown adipose tissue derived VEGF-A modulates cold tolerance and energy expenditure. Mol Metab 2014; 3: 474–483. doi:10.1016/j.molmet.2014.03.010 PMID: 24944907

28. Sung HK, Doh KO, Son JE, Park JG, Bae Y, Choi S, et al. Adipose vascular endothelial growth factor regulates metabolic homeostasis through angiogenesis. Cell Metab 2013; 17: 61–72. doi: 10.1016/j.cmet.2012.12.010 PMID: 23312284

29. Xue Y, Petrovic N, Cao R, Larsson O, Lim S, Chen S, et al. Hypoxia-independent angiogenesis in adipose tissues during cold acclimation. Cell Metab 2009; 9: 99–109. doi: 10.1016/j.cmet.2008.11.009 PMID: 19117550

30. Elias I, Franckhauser S, Ferre T, Vila L, Tafuro S, Munoz S, et al. Adipose tissue overexpression of vascular endothelial growth factor protects against diet-induced obesity and insulin resistance. Diabetes 2012; 61: 1801–1813. doi:10.2337/db11-0832 PMID: 22522611

31. Cannon B, Nedergaard J. Brown adipose tissue: function and physiological significance. Physiol Rev 2004; 84: 277–359. PMID: 14715917

32. Sidossis L, Kajimura S. Brown and beige fat in humans: thermogenic adipocytes that control energy and glucose homeostasis. J Clin Invest 2015; 125:478–486. doi: 10.1172/JCI78362 PMID: 25642708

33. Cypess AM, Haft CR, Laughlin MR, Hu HH. Brown fat in humans: consensus points and experimental guidelines. Cell Metab 2014; 20: 408–415. doi: 10.1016/j.cmet.2014.07.025 PMID: 25185947